Cormedix Received the US FDA’s Approval for DefenCath to Reduce Catheter-Related Bloodstream Infections (CRBSI) In Adult Hemodialysis Patients
Shots:
- The approval was based on the P-III (LOCK-IT-100) study evaluating the safety & efficacy of DefenCath vs heparin (control) as a Catheter Lock Solution (CLS) to reduce CRBSIs in patients (n=806) with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC)
- The result depicted a lower incidence of CRBSI in patients in the DefenCath cohort vs the control group with a Hazard Ratio of 0.29 thereby indicating a statistically significant reduction in risk of developing a CRBSI by 71%
- DefenCath is a CLS that helps prevent infection. It contains heparin & taurolidine, an antimicrobial agent designed to occupy the catheter lumen in between sessions of dialysis
Ref: CorMedix | Image: CorMedix
Related News:- CorMedix Reports Results of Neutrolin in P-III LOCK-IT-100 Study for Patients with Hemodialysis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
